Анализ акций INDSWFTLTD.NS
IN
Нет оценки
Количественный анализ Eyestock не покрывает акции Ind Swift Ltd.
Капитализация млрд. $
0.003
Дивидендная доходность
—
Оборот
54.165 млрд
Сайт компании
http://www.indswiftltd.com/Ind-Swift Ltd. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Chandigarh, Chandigarh. The firm operates in both domestic and export markets. The company is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The firm is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. The company operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The firm also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. The company has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The firm also has five plants in India.